Experimental validation of candidate alzheimer's disease treatments identified by multi-omics analyses
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95022D00012
- Awardee
-
Scantox Neuro GMBH UEI ED41XCPBEPU1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 3 $2,326,159 obligated
Award facts
- Combined order value
- $2,326,159 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 100% used
- $2,326,159.08
- Award type
- Single award
- Who can order
- Only the awarding agency
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging (NIA) awarded a $2,326,159.08 Indefinite Delivery Contract (IDC) to the prime contractor QPS Austria GmbH, a for-profit contract research organization. The IDC, which has a period of performance through May 31, 2025, is to provide experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses under the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. The contracted services involve testing these candidate treatments in transgenic Alzheimer's mouse models to determine their effects on disease pathology and progression. The contract does not have any set-aside designation and the work will be performed in Austria by the prime contractor.
Under the IDC, the NIA has awarded three firm fixed price delivery orders to QPS Austria GmbH to date, valued at $858,106.08, $830,053.00, and $638,000.00 respectively. These delivery orders cover the experimental validation work across different performance periods through May 2025. The IDC and associated task orders aim to advance the development of new Alzheimer's disease treatment options identified through the NIA's DREAM study, which utilizes multi-omics analyses to repurpose existing drugs.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95022D00012?
75N95022D00012 was awarded to Scantox Neuro GMBH by National Institute on Drug Abuse (National Institutes of Health) on June 1, 2022.
How much is contract 75N95022D00012 worth?
Orders under 75N95022D00012 have obligated $2,326,159. 75N95022D00012's own ceiling is $2,326,159.
How many orders have been placed under contract 75N95022D00012?
3 orders have been placed under 75N95022D00012, the latest on June 1, 2024.
Which agency awarded contract 75N95022D00012?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022D00012, with funding from National Institute on Aging (National Institutes of Health).
Who can order from contract 75N95022D00012?
75N95022D00012 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95022D00012 competed?
The extent of competition for 75N95022D00012 was competed under sap. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV